DNTH · Dianthus Therapeutics, Inc.

The thesis

Dianthus Therapeutics' claseprubart case rests on the MoMeNtum Phase 2 result in multifocal motor neuropathy (MMN), which the company guides for the fourth quarter of 2026. The adjusted close was $78.53 on 22 October 2026, 32.3% below the $115.96 adjusted 52-week high. The randomized data settles whether the decline reverses.

The 14-day relative strength index (a momentum gauge where readings under 30 mark heavy selling) was 29.7 on 22 October 2026. The three-month price change was -24.8%. The 25 September 2026 weekly close of $88.55 has been breached, and the latest close sits below it.

The narrative is maturing: 15 analysts cover the name (MarketBeat, 8 October 2026), HC Wainwright reiterated a Buy rating and $158 target on 15 October 2026, and the shares have kept falling since the 18 September 2026 registration filing. The latest company news item found since the prior note is a 13 October 2026 workplace-ranking release; no clinical update has been issued since the 4 August 2026 results release.

Bullish and bearish views on Dianthus Therapeutics, Inc.

The bull case on Dianthus Therapeutics, Inc. (DNTH), in brief: Open-label response supports randomized testing. The bear case: Price keeps falling before data.

Bull case

• Open-label response supports randomized testing. Dianthus reported a 75% response rate among the first 40 CAPTIVATE Part A completers in its 12 June 2026 filing. The study is in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease, and has no control arm at this stage.
• Cash funds the guided calendar. The 4 August 2026 results release reported about $1.2 billion in cash and investments at 30 June 2026, and management guided to a runway into 2030.
• The readout tests the molecule against control. MoMeNtum top-line data are guided for the fourth quarter of 2026. A positive randomized result would be the first controlled evidence for claseprubart.
• Analysts sit far above the price. MarketBeat reported a consensus target of $129.83 on 8 October 2026. HC Wainwright's target is $158 (reiterated 15 October 2026), JPMorgan's is $135 (initiated 11 September 2026) and Citi's is $156 (initiated 4 September 2026).

Bear case

• Price keeps falling before data. The close on 22 October 2026 was $78.53, below the $88.55 weekly close of 25 September 2026. MarketBeat put the 50-day moving average at $103.75 and the 200-day at $94.48 on 8 October 2026, and the shares trade below both.
• Stock-sale capacity is open. Dianthus filed an automatic registration statement on 18 September 2026 with a supplement for up to $500 million of common stock. No completed sales appeared in company news through 22 October 2026.
• Insiders sold into strength. MarketBeat's summary of Form 4 filings shows 242,429 shares sold for about $26.1 million over three months.
• One drug carries every readout. Claseprubart spans CIDP, generalized myasthenia gravis and MMN. A failed MoMeNtum result would weigh on views of the other programs.

Price setup

The adjusted close of $78.53 on 22 October 2026 is 32.3% under the 52-week high of $115.96. The shares sit below the 50-day and 200-day averages, so no gap above a rising average exists. MarketBeat reports a 52-week low of $32.22 on unadjusted prices.

A daily close below $75 would extend the decline. A weekly close back above $100 would be the first sign of repair, since it would reclaim the level lost in September.

Crowding evidence is mixed. Sell-side coverage is wide, insider sales were heavy in August and September, and the registered stock-sale capacity is open. Earnings are expected near 5 November 2026, though the company has not confirmed the date.

Catalysts, next 30 days

• Fourth quarter 2026: MoMeNtum top-line data. The company guides to the quarter, not a day. An early-December release is an estimate and falls outside the next 30 days.
• ~31 December 2026, est.: CAPTIVATE Part B timing. A dated calendar would settle how long the wait for pivotal CIDP data runs.

Elapsed catalysts

• ~5 November 2026, est.: Q3 2026 results. The company has not confirmed the date; it reported Q3 2025 on 5 November 2025. The release can confirm MoMeNtum timing and disclose any stock sales under the registration. (passed 1d ago)

What would change the view

The case breaks if MoMeNtum misses its prespecified primary endpoint against control, or if Dianthus sells common stock under the 18 September 2026 registration at a price well below recent levels. A company statement that moves the MoMeNtum readout out of the fourth quarter of 2026 would also weaken it.

On price, a daily close below $75 would extend the decline. A weekly close above $100 would argue the selling has ended.

What it trades with

Dianthus trades on its own clinical calendar. Its moves track clinical-stage biotech sentiment and the read-through from other neuromuscular and complement-pathway antibody results. Claseprubart's three indications mean one readout can move the shares on all of them.